Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

Stephane A Régnier¹

William Malcolm²

Jennifer Haig³

Weiguang Xue⁴

¹Novartis Pharma AG, Basel, Switzerland; ²Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; ³Optum, Burlington, ON, Canada; ⁴Optum, Uxbridge, UK

Background: Ranibizumab and aflibercept are alternative anti-vascular endothelial growth factor agents approved for the treatment of visual impairment (VI) due to diabetic macular edema (DME).

Objective: To estimate, from a UK healthcare perspective, the cost-effectiveness of ranibizumab 0.5 mg *pro re nata* (PRN) and ranibizumab 0.5 mg treat and extend (T&E) compared with aflibercept 2 mg every 8 weeks after five initial monthly doses (2q8) in the treatment of VI due to DME.

Methods: A Markov model previously reviewed by the National Institute for Health and Care Excellence was used to simulate the long-term outcomes and costs of treating DME. Health states were defined by increments of ten letters in best-corrected visual acuity (BCVA), with a 3-month cycle length. Patients could gain (or lose) a maximum of two health states between cycles. A 3-year treatment time frame and a lifetime horizon were used. Future costs and health outcomes were discounted at 3.5% per annum. Patient baseline characteristics and the efficacy of ranibizumab PRN were derived using data from the RESTORE study. The relative efficacies of ranibizumab PRN, ranibizumab T&E, and aflibercept were assessed with a network meta-analysis. Different utilities were assigned based on BCVA and whether the treated eye was the better- or the worse-seeing eye. Sensitivity analyses tested the robustness of the model.

Results: Lifetime costs per patient of treating DME were £20,019 for ranibizumab PRN, £22,930 for ranibizumab T&E, and £25,859 for aflibercept 2q8. Ranibizumab was dominant over aflibercept, with an incremental gain of 0.05 quality-adjusted life-years (QALYs) and cost savings of £5,841 (PRN) and £2,930 (T&E) compared with aflibercept. Ranibizumab PRN and ranibizumab T&E had 79% and 67% probability, respectively, of being cost-effective relative to aflibercept at a willingness-to-pay threshold of £20,000/QALY. When assuming the higher end of PRN injection frequency (15.9 over 3 years), the cost savings associated with ranibizumab were £3,969.

Conclusion: From a UK healthcare perspective, ranibizumab provides greater health gains with lower overall costs than aflibercept in patients with VI due to DME.

Keywords: Markov model, cost-utility, health states, macula, retina

Correspondence: Stephane A Régnier
Novartis Pharma AG Novartis Campus,
Fabrikstrasse 6, CH-4056, Basel,
Switzerland
Tel +41 61 535 5607
Email stephane.regnier@novartis.com

Introduction

Diabetic macular edema (DME) is the leading cause of blindness in patients with diabetic retinopathy.¹ It is characterized by vascular leakage, tissue edema, and the deposition of hard exudates in the central retina.²⁻⁴ With regard to the socioeconomic burden of the disease, DME can lead to visual impairment (VI) with consequent

reduction in quality of life,^{5–7} and patients with DME consume significantly more healthcare resources than diabetic patients without retinal complications.⁸ The Pan-European Prevalence Assessment of Diabetic Macular Edema with Visual Impairment (PREVAIL) study reported an overall prevalence (among diabetic patients) of DME of 5.4%, with a prevalence of VI due to DME of 1.9%.⁹ Given that the prevalence of diabetes mellitus has already reached epidemic proportions worldwide, and is projected to increase further over the next 20 years,¹⁰ it is expected that VI due to DME will continue to be a significant public health problem for the foreseeable future.

The etiology of DME is complex and has not been fully elucidated. Chronic hyperglycemia, the accumulation of oxygen free radicals and advanced glycation end products, and high cholesterol levels have all been implicated as risk factors for the development of DME.¹¹ However, the breakdown of the blood–retinal barrier (BRB) has been recognized as a defining event in the disease process.¹² In addition, vascular endothelial growth factor (VEGF)-A has been identified as a key vascular permeability factor that contributes to neovascularization and BRB dysfunction,¹³ making it an attractive target for pharmaceutical intervention.

Ranibizumab is a monoclonal anti-VEGF-A antibody fragment administered by intravitreal injection. The results of the RIDE and RISE studies, two randomized, multicenter, phase 3 trials, showed that ranibizumab improved visual acuity and retinal anatomy in patients with DME when compared with sham injections.^{14,15} In the RIDE study, 19.2% of patients in the sham injection group gained at least 15 letters, compared with 36.8% of patients in the ranibizumab 0.3 mg group ($P<0.0001$) and 40.2% of patients in the ranibizumab 0.5 mg group ($P<0.001$). In RISE, the proportions were 22.0%, 51.2%, and 41.6%, respectively. In the phase 3 RESTORE study, ranibizumab monotherapy and ranibizumab combined with laser therapy provided greater gains in visual acuity than standard laser treatment in patients with VI due to DME.¹⁶

Based on these results, ranibizumab became the first drug to receive approval from the European Medicines Agency (EMA) for the treatment of VI due to DME.¹⁷ A second anti-VEGF agent, aflibercept, recently received EMA approval for the treatment of VI due to DME¹⁸ based on results from two phase 3 trials, the VEGF Trap-Eye in Vision Impairment Due to DME (VIVID-DME) study and the study of Intravitreal Administration of VEGF Trap-Eye in Patients with DME (VISTA-DME), which demonstrated significant ($P<0.0001$) superiority in functional and anatomic endpoints over laser therapy.¹⁹

Given the substantial socioeconomic burden of VI due to DME, it is important to evaluate the cost-effectiveness of novel therapies for this condition. The objective of this study was to compare, from a UK healthcare perspective, the cost-effectiveness of ranibizumab 0.5 mg *pro re nata* (PRN) and ranibizumab 0.5 mg treat and extend (T&E) with 2 mg aflibercept every 8 weeks after five initial monthly doses (2q8).

Methods

Model structure

A Markov decision-analytical model that was submitted to the UK National Institute for Health and Care Excellence (NICE) was updated and revised to predict the long-term costs and health outcomes of ranibizumab treatment for VI due to DME.^{20,21} The model submitted to NICE was populated using data from the RESTORE study.¹⁶ The model followed a cohort of patients whose baseline characteristics were derived from those of patients in the RESTORE study,¹⁶ in which 66% of individuals had a baseline best-corrected visual acuity (BCVA) between 56 and 75 letters (Table 1). As per the RESTORE population, it was assumed that 60% of patients were treated in their worse-seeing eye (WSE), 18% were treated in their better-seeing eye (BSE), and 22% were treated in both eyes (ie, in both BSE and WSE). In the Markov model, patients cycled between eight health states, defined by BCVA intervals ranging from ≤ 25 letters to 86–100 letters in the treated eye, and a ninth, absorbing, “death” state (Figure 1). Figure 1 illustrates that patients could move up or down a maximum of two health states within each cycle (3 months) over a lifetime horizon. The lifetime horizon is defined as the time period over which the cost and benefits of the 3-year treatment is evaluated. A half-cycle correction was applied to each cycle.

Table 1 Baseline ocular characteristics of patients followed in the model

BCVA (letters)	Patients (%)
86–100	0
76–85	11
66–75	39
56–65	27
46–55	15
36–45	8
26–35	0
≤ 25 letters	0
Patients treated in both eyes	22
Patients treated in WSE	60
Patients treated in BSE	18

Abbreviations: BCVA, best-corrected visual acuity; WSE, worse-seeing eye; BSE, better-seeing eye.

Figure 1 Markov model structure showing health states and possible patient transitions between states.

Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.

The timeframe of anti-VEGF treatments was assumed to be 3 years. In the first, second, and third year, transition probabilities (TPs) were calculated for ranibizumab 0.5 mg PRN using the full analysis set with 3 years of data from the RESTORE study. From year 4 onward, patients were assumed to not receive any ranibizumab or aflibercept treatment, and TPs were calculated using data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR)^{22,23} to capture the natural decline in BCVA without treatment. As there are no published head-to-head trials comparing the efficacy of ranibizumab and aflibercept, the first-year TPs for aflibercept-treated patients gaining ten or more letters (ie, one or two health states) were calculated using data from a published network meta-analysis.²⁴ In this analysis of eight randomized clinical trials, the efficacy of ranibizumab PRN, as measured by the percentage of patients who gained at least ten letters, was numerically superior to aflibercept (odds ratio [OR], 1.59; 95% credible interval [CrI], 0.61–5.37). The analysis adjusted for different baseline BCVAs across clinical trials. The percentages of patients losing ten or more letters between two cycles were assumed to be the same in the aflibercept and ranibizumab PRN groups. This assumption was justified by the low number of patients in the VIVID-DME, VISTA-DME,¹⁹ and RESTORE¹⁶ clinical trials who lost significant vision (one patient in the aflibercept 2q8 arms in VIVID-DME and VISTA-DME, and one patient in the ranibizumab 0.5 mg PRN arm in RESTORE lost 15 or more letters). From year 1 onward, the same TPs were assumed for aflibercept and ranibizumab PRN because no meta-analysis was available after year 1. To assess the sensitivity of the results to this assumption, we also assumed, in the sensitivity analysis, a treatment timeframe of 1 year followed by natural decline in BCVA without treatment.^{22,23} The calculations of aflibercept TPs are summarized in Table S1.

For the ranibizumab 0.5 mg T&E regimen, the previously published network meta-analysis was updated by adding the results from the RETAIN study²⁵ to the network. The primary objective of RETAIN was to demonstrate non-inferiority, measured by mean change from baseline in BCVA over a 12-month treatment period, of either ranibizumab 0.5 mg T&E or the combination of ranibizumab T&E and laser versus ranibizumab 0.5 mg PRN. In the study, a patient receiving the T&E regimen (and PRN regimen) received monthly injections of ranibizumab 0.5 mg until BCVA was stabilized (with a minimum of three initial monthly injections). At the visit at which stabilization was confirmed, the patient received no treatment. The first T&E visit followed 1 month after the visit at which stabilization was confirmed. If there was no loss of BCVA that could be attributed to DME, the treatment-free period was increased by one more month. The maximal time between injection visits was 3 months. If visual acuity decreased due to DME, the patient resumed monthly treatment and BCVA stability was required before re-entering the extension treatment phase. An approach similar to that used for aflibercept was used to calculate TPs for the ranibizumab T&E regimen.

Utilities

Utilities for each health state were assigned based on BCVA and whether the treated eye was the BSE or WSE, as defined by Bressler et al.²⁶ The assumptions made in calculating utilities were based on the 2013 ranibizumab for DME appraisal by NICE.²¹ Data from Czoski-Murray et al²⁷ were used for the BSE, with a utility range of 0.497 between best and worst possible states; for the WSE, a utility decrement of 0.1 was assumed between the best and worst possible states. The mapping between utilities, BSE/WSE, and BCVA is presented in Table 2. Consistent with the NICE assessment of aflibercept in neovascular

Table 2 Utilities used by BCVA level and eye status

BCVA (letters)	BSE	WSE
86–100	0.850	0.8500
75–85	0.758	0.8357
66–75	0.685	0.8214
56–65	0.611	0.8071
46–55	0.537	0.7929
36–45	0.464	0.7786
26–35	0.390	0.7500
≤25 letters	0.353	0.7500

Notes: The utilities for the BSE were calculated using the following formula: Utilities = $-0.86 - 0.368 * \text{LogMar} - 0.001 * \text{age}$ with the age set at 65 years.²⁷

Abbreviations: BCVA, best-corrected visual acuity; BSE, better-seeing eye; WSE, worse-seeing eye; LogMar, logarithm of the minimum angle of resolution.

age-related macular degeneration, it was assumed that the rate of adverse events (AEs) for ranibizumab and aflibercept was equal.²⁸ This assumption is reviewed in the “Discussion” section.

Resource use

Ranibizumab and aflibercept treatment and monitoring frequencies are summarized in Table 3. Ranibizumab PRN treatment frequencies in years 1, 2, and 3 (and monitoring frequencies in year 1) were taken from the RESTORE study.¹⁶ Ranibizumab monitoring frequencies in years 2 and 3 were obtained from the Diabetic Retinopathy Clinical Research Network (DRCR.net) study.²⁹ The rationale for using the monitoring data from DRCR.net instead of RESTORE is that the RESTORE protocol used monthly monitoring, which is no longer required by the updated

European label.³⁰ The impact of assuming monthly monitoring rather than monitoring as per the DRCR.net study was assessed and presented in the sensitivity analyses. Aflibercept treatment frequencies in year 1 were the mean frequencies in VIVID-DME and VISTA-DME.¹⁹ Mean treatment frequencies in year 2 were calculated using the VISTA-DME study.¹⁹ To our best knowledge, the mean frequency in year 2 of the VIVID-DME study was not published at the time this manuscript was written. Ranibizumab T&E injection frequency was taken from RETAIN.²⁵ Aflibercept and ranibizumab T&E treatment frequency in year 3 was assumed to be the same as in year 2 because no clinical data were available at the time of the analysis. No additional monitoring visits were assumed for aflibercept and ranibizumab T&E.

Costs

The model estimated the costs and clinical benefits of ranibizumab and aflibercept treatment from the perspective of the UK National Health Service. Future costs and health outcomes were discounted at 3.5% per annum, according to the NICE reference case. The costs used in this analysis are summarized in Table 4. The cost of blindness was associated with individuals whose BCVA was less than 35 letters (Table S2).

Economic analysis

The incremental cost-effectiveness ratio (ICER) was calculated as the ratio of the mean incremental cost and the mean

Table 3 Key model inputs for the base-case scenario

Time period	Model input	Ranibizumab 0.5 mg PRN	Ranibizumab 0.5 mg T&E	Aflibercept 2q8
Year 1	BCVA data source for TPs	RESTORE ¹⁶	Network meta-analysis	Network meta-analysis + assumptions
	Treatments (n)	7.0 (RESTORE) ¹⁶	7.7 (RETAIN) ²⁵	8.5 (VIVID-DME/VISTA-DME) ¹⁹
	Monitoring visits (n)	12.0 (RESTORE) ¹⁶	7.7 (assumptions)	8.5 (VIVID-DME/VISTA-DME) ¹⁹
Year 2	BCVA data source for TPs	RESTORE extension ⁴⁰	Assumptions (same TPs as ranibizumab PRN)	Assumptions (same TPs as ranibizumab PRN)
	Treatments (n)	3.9 (RESTORE extension) ⁴⁰	5.1 (RETAIN) ²⁵	5.1 (VISTA-DME) ^{19,42}
	Monitoring visits (n)	9.0 (DRCR.net) ^{29,a}	5.1 (assumptions)	5.1 (VISTA-DME) ^{19,42}
Year 3	BCVA data source for TPs	RESTORE extension ⁴⁰	Assumptions (same TPs as ranibizumab PRN)	Assumptions (same TPs as ranibizumab PRN)
	Treatments (n)	2.9 (RESTORE extension) ⁴⁰	5.1 (assumptions – same as in year 2)	5.1 (assumptions – same as in year 2)
	Monitoring visits (n)	7.5 (DRCR.net) ^{29,a}	5.1 (assumptions – same as in year 2)	5.1 (assumptions – same as in year 2)
Year 4+	BCVA data source	Natural history ^b	Natural history ^b	Natural history ^b
	Treatments (n)	0 (assumption)	0 (assumption)	0 (assumption)
	Monitoring visits (n)	0 (assumption)	0 (assumption)	0 (assumption)

Notes: ^aAverage monitoring visits between ranibizumab plus prompt laser treatment and ranibizumab plus deferred laser treatment arms DRCR.net;²⁹ ^bnatural history refers to the WESDR study.^{22,23}

Abbreviations: PRN, *pro re nata*; T&E, treat and extend; 2q8, 2 mg every 8 weeks after five initial monthly doses; BCVA, best-corrected visual acuity; TP, transition probability.

Table 4 Key treatment cost assumptions

	Cost (£)	Source
Ranibizumab price/vial	742.17	NICE ²⁸
Aflibercept price/vial	816.00	NICE ²⁸
Visit with injection ^a	168.53	UK Department of Health ⁴³
Visit without injection (monitoring visit)	60.00	NICE ²⁸

Notes: ^aCost of optical coherence tomography (£51.27) + injection visit (£117.26); excludes drug costs. The cost of optical coherence tomography was estimated to be the same as an outpatient diagnostic procedure coded as an ultrasound scan of less than 20 minutes ie, £51.27 (HRG code, RA23Z). The ranibizumab injection administration visit was coded as an office-based outpatient procedure (£117.26 [HRG code, BZ23Z] Vitreous Retinal Procedures – category I).

Abbreviations: NICE, National Institute for Health and Care Excellence; HRG, healthcare resource group.

number of incremental quality-adjusted life-years (QALYs) for ranibizumab regimens compared with aflibercept. Net monetary benefit (NMB) was calculated assuming a willingness to pay £20,000/QALY.³² The NMB is equal to the sum of cost savings (or incremental costs) plus QALY gains multiplied by £20,000. A higher NMB indicates greater value: an NMB greater than £0 is equivalent to an ICER <£20,000/QALY. Thus, in the context of this analysis, cost-effective is defined as meeting the accepted standards of cost-effectiveness based on a willingness-to-pay threshold of £20,000/QALY.

Sensitivity analyses

Deterministic sensitivity analysis was used to explore uncertainty around individual input values to the model, and the effect on the resultant NMB was calculated. In particular, since net drug prices are not publicly available, the impact of a price discount was analyzed. Probabilistic sensitivity analysis (PSA) (1,000 iterations) was used to model joint parameter uncertainty, enabling cost-effectiveness acceptability curves (CEACs) to be calculated. The probability distributions chosen for the PSA were based on those recommended for health economic analysis.³³ Standard errors of aflibercept injections were not known in year 2 and year 3, and the same standard deviation as ranibizumab PRN was assumed. The variables with varying values in the PSA are included in Table S3.

Table 5 Base-case cost-effectiveness results per patient

Comparison	Total cost (£)	Total QALY	Incremental cost (£)	Incremental QALY	NMB (£) ^a
Aflibercept 2q8	25,859	8.54			
Ranibizumab 0.5 mg PRN	20,019	8.59	–5,841	0.05	6,768
Ranibizumab 0.5 mg T&E	22,930	8.59	–2,930	0.05	3,934

Notes: ^aAssumes willingness-to-pay threshold of £20,000/QALY.

Abbreviations: QALY, quality-adjusted life-year; NMB, net monetary benefit; 2q8, 2 mg every 8 weeks after five initial monthly doses; PRN, *pro re nata*; T&E, treat and extend.

Results

Health outcomes

Based on the published (PRN) and updated network meta-analysis (T&E), the ranibizumab 0.5 mg PRN and ranibizumab 0.5 mg T&E regimens were both numerically favored over aflibercept 2q8 in terms of the percentage of patients who gained at least ten letters in BCVA: OR, 1.59 (95% CrI, 0.61–5.37) and OR, 1.65 (95% CrI, 0.38–8.94), respectively.

Base case

Ranibizumab PRN and T&E regimens were associated with a QALY gain per patient of 0.05 over aflibercept (Table 5). Lifetime costs per patient were substantially lower for ranibizumab PRN (–£5,841) and ranibizumab T&E (–£2,930) than for aflibercept. Ranibizumab led to greater health gains at lower cost and was therefore dominant over aflibercept. The NMB was £6,768 for ranibizumab PRN and £3,934 for ranibizumab T&E at a willingness-to-pay threshold of £20,000/QALY (Table 5). The main drivers of the base-case results were the greater number of aflibercept injections required compared with ranibizumab injections, the higher efficacy assumptions of ranibizumab (PRN and T&E) relative to aflibercept, and higher costs associated with aflibercept compared with ranibizumab regimens.

Sensitivity analyses

Deterministic sensitivity analysis showed that the results were robust to variations in key model parameters (Figure 2). The parameter with the most impact was the OR for the percentage of patients gaining ten or more letters. However, even by using the lower end of the CrI from the network meta-analysis (0.61), the NMB of ranibizumab PRN was positive (£3,592). Similarly, the NMB was positive even if the higher end of the 95% confidence interval (CI) of the injection frequency (15.9 injections over 3 years) was assumed for ranibizumab PRN (£4,897) representing a cost saving of £3,969. Under the assumption that the price of aflibercept was 20% lower than assumed in the base case (ie, £653 vs £742/dose for ranibizumab), ranibizumab PRN

Figure 2 Tornado plots of one-way sensitivity analyses for ranibizumab 0.5 mg PRN compared with aflibercept 2q8.

Notes: The NMB in the base-case scenario is £6,768 for ranibizumab 0.5 mg PRN versus aflibercept. Model parameters varied in the sensitivity analyses are shown on the Y axis. The first model parameter in brackets was used to obtain the lower NMB while the second model parameter was used to obtain the higher NMB.

Assumptions used to determine the input range for the tornado plot: Ranibizumab PRN versus aflibercept OR values are based on the 95% CrI from the published network meta-analysis.²⁴ The range in the number of ranibizumab PRN injections over 3 years was based on the 95% confidence interval from the RESTORE 36-month data.⁴⁰ The range in the number of PRN injections in the first year was based on the weighted injection average across RESTORE¹⁶ and RESPOND.⁴¹ The lower value for the number of aflibercept injections assumed the same injection frequency as the ranibizumab PRN regimen. Ranibizumab maximal monitoring frequency assumed monthly monitoring (as described in the RESTORE protocol).¹⁶

Abbreviations: PRN, *pro re nata*; 2q8, 2 mg every 8 weeks after five initial monthly doses; NMB, net monetary benefit; CrI, credible interval.

still provided a positive NMB compared with aflibercept bimonthly (£3,530). Ranibizumab PRN remained dominant when a higher number of PRN injections were assumed: eg, 7.9 instead of 7.0 injections resulted in an NMB of £5,863 in the first year (Figure 2). Using monthly monitoring instead of DRCR.net²⁹ monitoring assumptions for ranibizumab PRN, changing the cost of monitoring visits, and changing the aflibercept injection frequency in the third year (post-VISTA-DME results) all had limited impact on the results. Specifically, monthly monitoring decreased the NMB of ranibizumab PRN by £354, while doubling the monitoring costs reduced the NMB of ranibizumab PRN by £764.

The PSA showed that ranibizumab PRN had a 79% probability (Figure 3a) and ranibizumab T&E a 67% probability (Figure 3b) of being cost-effective compared with aflibercept at a willingness-to-pay threshold of £20,000/QALY. There were no simulations in which ranibizumab PRN was found to be more effective and more costly than aflibercept (upper-right quadrant). In the PSA, we allowed the natural history curves after year 3 to be different for ranibizumab and aflibercept. If we impose the constraint that the curves should be the same, then ranibizumab PRN has a 99% probability of being cost-effective compared with aflibercept at a willingness-to-pay threshold of £20,000/QALY (result not shown). Ranibizumab PRN had a 74% probability of being cost-effective compared with aflibercept when 7.9 PRN injections instead of 7.0 were assumed in the first year. The CEACs comparing ranibizumab PRN and ranibizumab T&E with aflibercept are relatively flat (Figure 4a and b, respectively), indicating that the cost-effectiveness conclusions are independent of

the cost-effectiveness threshold. This is driven by the high proportion of simulations (65% in Figure 3a) that are located in the bottom-right (always cost-effective) or upper-left (never cost-effective) quadrants, which are not impacted by the level of the cost-effectiveness threshold.

When we assumed that ranibizumab 0.5 mg PRN and aflibercept 2q8 were only injected for 1 year (followed by natural progression of the disease), we also found that ranibizumab 0.5 mg PRN dominated aflibercept 2q8 (incremental QALY gained of 0.1 with incremental savings of £3,079 per patient). Approximately, two-third of the savings of £3,079 are generated by lower injection costs in the first year (1.54 less injections per eye or 1.9 less injections per patient with ranibizumab). Approximately, one-third of the savings are generated by lowering the number of blindness cases.

Discussion

To our knowledge, this is the first study to compare the cost-effectiveness of ranibizumab and aflibercept in the treatment of patients with VI due to DME. Our analyses showed that ranibizumab 0.5 mg PRN and ranibizumab 0.5 mg T&E (both licensed posologies) were both dominant over aflibercept 2q8, by demonstrating lower lifetime costs for UK healthcare providers as well as higher QALY gains for patients receiving ranibizumab than for those taking aflibercept. The main drivers of the results were the higher probability of gaining ten or more letters in BCVA with ranibizumab regimens compared with aflibercept 2q8,²⁴ the greater number of injections required, and higher costs

Figure 3 Scatter plots for probabilistic sensitivity analysis showing cost-effectiveness of (A) ranibizumab 0.5 mg PRN and (B) ranibizumab 0.5 mg T&E compared with aflibercept 2q8.

Abbreviations: QALY, quality-adjusted life-year; PRN, *pro re nata*; T&E, treat and extend; 2q8, 2 mg every 8 weeks after five initial monthly doses.

associated with aflibercept compared with ranibizumab treatment. The results were demonstrated to be robust by a number of univariate sensitivity analyses. In particular, the results were robust to a number of assumptions relating to ranibizumab PRN injection frequency. Ranibizumab 0.5 mg PRN and ranibizumab 0.5 mg T&E are individualized dosing regimens based on BCVA stability and disease progression criteria.¹⁶ Therefore, these results show the importance of an individualized regimen for the treatment of VI due to DME, because, on average, patients require

fewer injections in the second and third years of treatment than in the first year.

Costs are mainly driven by injection frequencies and cost of blindness. Since the 95% CI for the number of injections is narrow, the uncertainty around the number of injections has a limited impact on the sensitivity results. Since higher BCVA leads to lower VI costs, the relationship between incremental costs and QALYs is downward sloping (Figure 3a). In other words, while numerous variables were included in the PSA (Table S3), the PSA results are mainly driven by TPs.

Figure 4 Cost-effectiveness acceptability curves for **(A)** ranibizumab 0.5 mg PRN and **(B)** ranibizumab 0.5 mg T&E compared with aflibercept 2q8. **Abbreviations:** ICER, incremental cost-effectiveness ratio; PRN, *pro re nata*; T&E, treat and extend; 2q8, 2 mg every 8 weeks after five initial monthly doses.

For interventions that are more cost-effective than their comparators, CEACs from PSAs are typically upward sloping (ie, the higher the cost-effectiveness threshold, the higher the probability that a technology is cost-effective). This was not the case in this analysis because the only simulations impacted by a cost-effectiveness threshold were located in the bottom-left quadrant of the scatter plots (representing simulations in which ranibizumab was cheaper and less effective than aflibercept; Figure 3). In that quadrant, a higher cost-effectiveness threshold reduces the probability of being cost-effective.

A 0.05 QALY difference would yield a cost difference of £1,000 (assuming a cost per QALY gained of £20,000). Therefore, most of the NMB stems from cost reductions (including the cost of blindness) and not QALY gains. Real-world injection frequencies and net prices will be the key drivers of the real-world cost-effectiveness.

It was assumed that the frequency of AEs for ranibizumab and aflibercept was equal. However, in the VIVID-DME and VISTA-DME studies, five of 287 (1.7%) patients in the aflibercept 2q8 group experienced ocular serious AEs

(SAEs),¹⁹ whereas, in RESTORE, no ocular SAEs were reported in the first 12 months.¹⁶ Therefore, this assumption may be conservative. A meaningful comparison of the incidence of other SAEs in VIVID-DME, VISTA-DME, and RESTORE is difficult, because VIVID-DME and VISTA-DME reported systemic SAEs while RESTORE reported non-ocular SAEs.

Sensitivity analyses demonstrated that the model was robust to reasonable variations in model parameters and assumptions. A notable finding was that ranibizumab was still cost saving compared with aflibercept if the price of aflibercept was assumed to be the same as that of ranibizumab. The sensitivity analyses also showed that the results held even if we assumed that ranibizumab and aflibercept were only administered for 1 year (ie, if we did not make assumptions on the relative efficacy of the treatments after year 1).

This analysis assessed the cost-effectiveness of ranibizumab and aflibercept using regimens pre-defined in clinical trials. However, in real-world practice, physicians may use different treatment regimens.^{34,35}

A major limitation of this analysis is the lack of comparative efficacy data between ranibizumab 0.5 mg PRN and aflibercept 2q8 after year 1, due to the difficulties of updating the published network meta-analysis,²⁴ because half of the studies in the meta-analysis network did not report results after 1 year. Therefore, our model assumed an equivalent efficacy for ranibizumab and aflibercept after year 1. This assumption seems reasonable because, in VIVID-DME/VISTA-DME, the percentage of aflibercept 2q8 patients who gained ≥ 15 letters at year 2 was similar to the percentage of aflibercept 2q8 patients who gained ≥ 15 letters in year 1. The percentage of ranibizumab PRN patients who gained ≥ 15 letters was also similar in year 2 and year 1 (29% vs 26%, respectively).^{16,36} In addition, the rate of AEs with ranibizumab and aflibercept was assumed to be equal. This assumption is supported by a systematic review of the efficacy and safety of aflibercept, ranibizumab, and bevacizumab in neovascular age-related macular degeneration, which reported a similar frequency of SAEs for all three drugs.³⁷

While the VIVID/VISTA studies used a bimonthly aflibercept regimen in the second year, aflibercept has a T&E label in Europe.³⁸ We assumed 5.1 aflibercept injections in years 2 and 3 (as reported in VIVID/VISTA and in the ranibizumab T&E arm of RETAIN) but the lack of aflibercept injection data is a limitation of the current study.

A further limitation is that NICE recommends the use of ranibizumab 0.5 mg for the treatment of DME for eyes with a central retinal thickness of ≥ 400 μm at the start of

treatment, whereas our analysis included the whole patient population. The reason for this was that the published clinical data did not provide subgroup analyses for patients with a central retinal thickness ≥ 400 μm . It should be noted that the analysis did not include bevacizumab, a full-length anti-VEGF-A antibody developed for the treatment of cancer that is not licensed for VI due to DME. This is consistent with NICE guidance, which indicates that there is currently no robust evidence with which to assess the clinical effectiveness or safety of bevacizumab in the treatment of DME.²¹ Finally, the analysis did not include laser therapy because it has already been shown that ranibizumab provides superior visual acuity gain over standard laser treatment.¹⁶

Conclusion

In this economic analysis from a UK healthcare perspective, ranibizumab 0.5 mg PRN and T&E regimens were dominant over aflibercept 2q8 for the treatment of VI due to DME. Ranibizumab therapy resulted in lower lifetime costs and higher QALY gains than treatment with aflibercept, indicating that ranibizumab should be viewed as the new standard of care for DME. Cost-effectiveness evidence of the type presented here is valuable for formulary decision making in the UK National Health Service.

Acknowledgments

The authors would like to thank Fernando Gibson, PhD, from PharmaGenesis™, London, UK, for editorial support in developing the manuscript. This project was funded by Novartis Pharma AG, Basel, Switzerland.

Disclosure

Stephane Régner is an employee of Novartis Pharma AG and William Malcolm is an employee of Novartis Pharmaceuticals UK Ltd; Jennifer Haig and Weiguang Xue are employees of Optum and received payment from Novartis Pharma AG for this work. The abstract of this paper was presented at the 2014 ISPOR conference in Amsterdam, the Netherlands, as a poster presentation with interim findings. The poster's abstract was published in "Poster Abstracts" in the November 2014 issue of Value in Health. ([http://www.valueinhealthjournal.com/article/S1098-3015\(14\)04062-5/pdf](http://www.valueinhealthjournal.com/article/S1098-3015(14)04062-5/pdf)). The actual paper, however, has never been published.

References

1. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. *Curr Diab Rep*. 2012;12(4):346–354.
2. Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. *Drugs*. 2010;70(16):2171–2200.

3. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet*. 2010; 376(9735):124–136.
4. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. *Diabetes Care*. 2003;26(9):2653–2664.
5. Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M. Diabetic retinopathy and health-related quality of life. *Graefes Arch Clin Exp Ophthalmol*. 2009;247(2):267–272.
6. Lamoureux EL, Tai ES, Thumboo J, et al. Impact of diabetic retinopathy on vision-specific function. *Ophthalmology*. 2010;117(4):757–765.
7. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. *Health Qual Life Outcomes*. 2008;6:95.
8. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. *Curr Med Res Opin*. 2010;26(7): 1587–1597.
9. Delcourt C, Sivaprasad S, Bandello F, et al. Prevalence of diabetic macular edema (DME) in Europe: the Pan European Prevalence Assessment of DME with Visual Impairment (PREVAIL) study. [Submitted].
10. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract*. 2010;87(1): 4–14.
11. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. *Surv Ophthalmol*. 2009;54(1):1–32.
12. Klaassen I, Van Noorden CJ, Schlöglmann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. *Prog Retin Eye Res*. 2013;34:19–48.
13. Zhang X, Bao S, Hambly BD, Gillies MC. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. *Int J Biochem Cell Biol*. 2009;41(12):2368–2371.
14. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. *Ophthalmology*. 2012;119(4):789–801.
15. Brown DM, Nguyen QD, Marcus DM, et al; RISE and RIDE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology*. 2013;120(10):2013–2022.
16. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. *Ophthalmology*. 2011;118(4):615–625.
17. European Medicines Agency. *Assessment Report for Lucentis (Ranibizumab)*. EMA/13901/2011; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000715/WC500101009.pdf. Accessed October 7, 2014.
18. European Medicines Agency. *Assessment Report for Eylea (Aflibercept)*. EMA/430291/2014; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002392/WC500172846.pdf. Accessed October 7, 2014.
19. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. *Ophthalmology*. 2014;121(11):2247–2254.
20. Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. *Br J Ophthalmol*. 2012;96(5):688–693.
21. National Institute for Health and Care Excellence. *Ranibizumab for Treating Diabetic Macular Oedema (Rapid Review of Technology Appraisal Guidance 237) [TA274]*; 2013. Available from: <http://www.nice.org.uk/guidance/ta274>. Accessed October 7, 2014.
22. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. *Am J Epidemiol*. 1984;119(1):54–61.
23. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. *Arch Ophthalmol*. 1984;102(4):520–526.
24. Regnier S, Malcolm W, Allen F, Wright J, Bezlyak V. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. *PLoS One*. 2014;9(7):e102309.
25. Pruenste C, Group RS. Efficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN study. *Invest Ophthalmol Vis Sci*. 2014;55:E-Abstract 1700.
26. Bressler NM, Chang TS, Suñer IJ, et al; MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. *Ophthalmology*. 2010;117(4):747.e–756.e.
27. Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. *Value Health*. 2009;12(5):793–799.
28. National Institute for Health and Care Excellence. *Aflibercept Solution for Injection for Treating Wet Age-Related Macular Degeneration [TA294]*; 2013. Available from: <http://www.nice.org.uk/guidance/ta294>. Accessed October 7, 2014.
29. Elman MJ, Qin H, Aiello LP, Beck RW, et al; Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology*. 2012;119(11):2312–2318.
30. European Medicines Agency. *Lucentis: EPAR – Product Information*; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed March 4, 2015.
31. Campochiaro PA, Sophie R, Pearlman J, et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. *Ophthalmology*. 2014;121(1): 209–219.
32. Claxton K, Martin S, Soares M, et al. *Methods for the Estimation of the NICE Cost Effectiveness Threshold*. New York: University of York, Centre for Health Economics; 2013.
33. Briggs A, Claxton K, Sculpher M. *Decision Modelling for Health Economic Evaluation*. Oxford: Oxford University Press; 2006.
34. Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: changing trends in the management of diabetic macular edema at a single institution over the past decade. *Retina*. Epub January 14, 2015.
35. Petrella RJ, Blouin J, Davies B, Barbeau M. Prevalence, demographics, and treatment characteristics of visual impairment due to diabetic macular edema in a representative Canadian cohort. *J Ophthalmol*. 2012;2012:159167.
36. Lang GE, Berta A, Eldem BM, et al; RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. *Ophthalmology*. 2013;120(10):2004–2012.
37. Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. *Br J Ophthalmol*. 2015;99(2):141–146.
38. European Medicines Agency. *Eylea: EPAR – Product Information*; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002392/WC500135815.pdf. Accessed March 5, 2014.
39. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. *Ophthalmology*. 1987;94(7):761–774.

40. Schmidt-Erfurth U, Lang GE, Holz FG, et al; RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. *Ophthalmology*. 2014;121(5):1045–1053.
41. Efficacy and safety of ranibizumab monotherapy or combined with laser versus laser monotherapy in diabetic macular edema: the RESPOND study. *Can J Ophthalmol*. 2015. [In press].
42. Bakshi NK. Update on the VIVID-DME and VISTA-DME trials. *Ophthalmol Sci Update*; 2014. Available from: <http://www.ophtalmologyupdate.ca/crus/230-015%206-pages%20English.pdf>. Accessed October 15, 2014.
43. UK Department of Health. *2011–2012 NHS Reference Costs*; 2014. Available from: <https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012>. Accessed October 7, 2014.
44. Shyangdan D, Cummins E, Lois N, Royle P, Waugh N. *Dexamethasone Implants in the Treatment of Macular Oedema Due to Retinal Vein Occlusion: A Single Technology Appraisal*. Aberdeen Health Technology Assessment Group 2010; 2014. Available from: <http://www.nice.org.uk/nicemedia/live/13037/52883/52883.pdf>. Accessed October 7, 2014.
45. Hospital and Community Health Services. *HCHS Pay and Prices Series 2010–2011*; 2014. Available from: <http://www.info.doh.gov.uk/doh/finman.nsf/af3d43e36a4c8f8500256722005b77f8/276315c0677bf5478025796b00418a4d?OpenDocument>. Accessed October 16, 2014.
46. Personal Social Services Research Unit. *Unit Costs of Health and Social Care 2011*; 2014. Available from: <http://www.pssru.ac.uk/project-pages/unit-costs/2011/>. Accessed October 7, 2014.
47. Personal Social Services Research Unit. *Unit Costs of Health and Social Care 2003*; 2014. Available from: <http://www.pssru.ac.uk/project-pages/unit-costs/2003/>. Accessed October 7, 2014.
48. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. *Paying the Price (2008): the Cost of Mental Health Care in England to 2026*; 2014. Available from: <http://www.kingsfund.org.uk/publications/paying-price>. Accessed October 7, 2014.
49. Appleby J, Poteliakhoff E, Shah K, Devlin N. Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals. *J R Soc Med*. 2013;106(8):323–331.

Supplementary materials

Table S1 Calculation of aflibercept transition probabilities

	$t < 12$ months	$t \geq 12$ months
$j > i+2$	$A_{jt} = R_{jt} = 0\%$	$A_{jt} = R_{jt} = 0\%$
$j = i+1$ or $j = i+2$	$(A_{jt} * [1 - R_{jt}]) / (R_{jt} * [1 - A_{jt}]) = OR$	$A_{jt} = R_{jt}$
$j = i-1$ or $j = i-2$	$A_{jt} = R_{jt}$	$A_{jt} = R_{jt}$
$j < i-2$	$A_{jt} = R_{jt} = 0\%$	$A_{jt} = R_{jt} = 0\%$
$j = i$	$A_{ijt} = 1 - \sum_{j=1, j \neq i}^{j=8} A_{ijt}$	$A_{jt} = R_{jt}$

Notes: R_{jt} is the ranibizumab transition probability from state i ($1 \leq i \leq 8$) at time t (months) to state j at time $t+1$; A_{jt} is the aflibercept transition probability from state i at time t to state j at time $t+1$. OR is for the percentage of patients experiencing an improvement in BCVA of at least ten letters on the ETDRS scale, and is calculated so that, at month 12, the OR of gaining ten letters or more with ranibizumab (vs aflibercept) is equal to 1.59 (95% CrI, 0.61–5.37).²⁴

Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; OR, odds ratio; CrI, credible interval.

Table S2 Costs of visual impairment

Item	Proportion of blind population requiring service (%)	Annual unit cost of service (£)	Mean cost per person (£)	Source calculations/assumptions
Low vision aids	33.0	167.38	55	<ul style="list-style-type: none"> Shyangdan et al⁴⁴ 2003/04 cost inflated to 2010/11 cost using the HCHS index⁴⁵ Inflated cost is divided by two, assuming that the service applies every 2 years
Low vision rehabilitation	11.0	426.40	47	<ul style="list-style-type: none"> PSSRU 2011⁴⁶ Community occupational therapist (local authority) Cost per hour of client contact including training = £82 Length of contact per care episode = 5.2 hours (PSSRU 2003)⁴⁷ Inflated cost is divided by two, assuming that the service applies every 2 years
Residential care	30.0	51,090.00	15,327	<ul style="list-style-type: none"> PSSRU 2011⁴⁶ Health authority residential care for older people £982.50 establishment cost per permanent resident week Costs assumed 52 weeks per year
Community care	6.0	10,005.84	600	<ul style="list-style-type: none"> PSSRU 2011⁴⁶ Home care worker Typical home care package = 12.4 hours per week Based on a study of community care packages, it has been estimated that 6.76 hours are worked, on average, during weekdays (6.6 between 9 am and 5 pm and 0.16 hours 5 pm). On average, 0.55 hours are worked each on Saturday and Sunday Costs = £22 per hour face-to-face weekday contact (£27 per hour weekday evenings; £33 per hour Saturdays; £45 per hour Sundays) Total annual cost per care package = £192.42 per week × 52
Depression	38.6	2,291.00	884	<ul style="list-style-type: none"> McCrone et al⁴⁸ Cost per patient aged 65–74 = £2,000 per annum 2005/06 cost inflated to 2010/11 cost using the HCHS index⁴⁵
Hip replacement	5.0	6,617.00	331	<ul style="list-style-type: none"> NHS reference costs 2010/11⁴⁵ NHS Trusts Elective Inpatient HRG data⁴³ HRG HBI2B major hip procedures for non-trauma Category I with complications⁴⁹
Blind registration	94.5	86.00	81	<ul style="list-style-type: none"> Shyangdan et al⁴⁴ 2003/04 cost inflated to 2010/11 cost using the HCHS index⁴⁵ Inflated cost is divided by two, assuming that the service applies every 2 years
Total			17,325	
Total in subsequent years			17,245	

Abbreviations: HCHS, Hospital and Community Health Services; HRG, Health Care Resource Group; NHS, National Health Service; PSSRU, Personal Social Services Research Unit.

Table S3 Key variables with varying value in the probability sensitivity analysis

Variable	Base-case	Standard deviation	Distribution
OR of gaining ≥ 10 letters (ranibizumab PRN vs aflibercept 2q8)	1.59	1.21	Log normal
Transition probabilities			
ranibizumab PRN – Yr 1–3	Varies by state	Varies by state	Gamma
Annual worsening after Yr 3	4.5%	$\alpha = 5.5/\beta = 1$	Gamma
No change after Yr 3	92%	$\alpha = 92/\beta = 1$	Gamma
Annual improvement after Yr 3	3.5%	$\alpha = 4.5/\beta = 1$	Gamma
Regression model for BSE utility			
Constant	0.86	0.039	Normal
LogMAR coefficient	–0.368	0.045	Normal
Age coefficient	–0.001	0.002	Normal
Ranibizumab PRN injections			
Year 1	7.0	0.26	Normal
Year 2	3.9	0.38	Normal
Year 3	2.9	0.32	Normal
Aflibercept 2q8 injections			
Year 1	8.54	0.11	Normal
Year 2	5.10	0.38	Normal
Year 3	5.10	0.32	Normal
Costs of visual impairment			
BCVA <35 letters	£17,326	£3,465	Gamma

Note: The transition probabilities in the probability sensitivity analysis are normalized, so that they equal 100%.

Abbreviations: OR, odds ratio; PRN, *pro re nata*; 2q8, 2 mg every 8 weeks after five initial monthly doses; BSE, better-seeing eye; LogMar, logarithm of the minimum angle of resolution.

ClinicoEconomics and Outcomes Research

Dovepress

Publish your work in this journal

ClinicoEconomics & Outcomes Research is an international, peer-reviewed open-access journal focusing on Health Technology Assessment, Pharmacoeconomics and Outcomes Research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems

organization also constitute important areas of coverage. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal>